Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 32-36
© 2002 European Renal Association-European Dialysis and Transplant Association

IV.6.3 Solid organ cancers: prevention and treatment

Guidelines

J. All renal transplant recipients should have regular ultrasonography of their native kidneys (when applicable) for screening of renal cell carcinomas, which are observed at much higher incidence in both dialysed and transplant patients.

(Evidence level B)

K. Guidelines published for screening and prevention of solid organ cancers in the general population should be strictly applied to transplant recipients, who are in general at higher cancer risk, but would benefit equally or even greater.

(Evidence level B)

L. All male renal transplant recipients aged 50 and over should have a yearly prostate specific antigen (PSA) test prior to a regular digital rectal examination.

(Evidence level B)

M. All female renal transplant recipients should have a yearly cervical (PAP) smear together with regular pelvic examination and regular mammography, according to national recommendations where available.

(Evidence level B)

N. All renal transplant recipients should undergo a faecal occult-blood testing as a screening for colorectal cancer and other (pre-malignant) lesions, according to national recommendations where available.

(Evidence level B)

O. In all these conditions, it is recommended to reduce immunosuppression whenever possible.

(Evidence level C)

See also Guidelines in Part 1: I.5.1 A–C, pp. 6–7.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
R. D. Kilpatrick, C. W. Critchlow, S. Fishbane, A. Besarab, C. Stehman-Breen, M. Krishnan, and B. D. Bradbury
Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1077 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
L. Zhang, L. Zuo, G. Xu, F. Wang, M. Wang, S. Wang, J. Lv, L. Liu, and H. Wang
Community-based screening for chronic kidney disease among populations older than 40 years in Beijing
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1093 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, S. Andrulli, B. Memoli, C. Maffei, L. Del Vecchio, S. Aterini, W. De Simone, A. Mandalari, G. Brunori, M. Amato, et al.
Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 991 - 998.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.